Agilent Technologies, Inc. (A) Stock

Agilent Technologies, Inc. (A) is a Technology stock trading at $156.29 (as of 2026-08-20), with a market capitalization of $44.17B and a trailing P/E of 31.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Agilent Technologies supplies application-specific products for the life sciences, diagnostics, and applied chemical markets. Its Life Sciences and Applied Markets segment covers analytical instrumentation, assays and lab software/information management, while its Diagnostics and Genomics segment supports DNA and gene analyses such as genotyping, sequencing-related workflows, and genetic data management.

Understand Agilent Technologies, Inc.: how it makes money

Agilent provides application-focused laboratory solutions for life sciences, diagnostics, and applied chemical markets, selling analytical instruments and components, and also offering CrossLab laboratory services.

Agilent’s profit model links sales of analytical systems and components (Life Sciences and Applied Markets) with services revenue from its CrossLab business, so results depend on both instrument demand and the continuation or expansion of lab services.

Revenue by segment (latest quarter)
LSAG$1.1B
ACG$0.8B

Business quality (Mixed): Clear reportable segment labels are available (LSAG and ACG), and the provided operating KPIs include segment revenue and CrossLab services revenue, which fit how the business is managed.

Valuation: At 27× earnings, A trades 54% below the Measuring & Control Equipment average (60×). Note: one-time items can distort reported P/E.

Bull case

  • Portfolio spans multiple instrument families used in lab workflows: Agilent’s Life Sciences and Applied Markets segment covers liquid chromatography, liquid chromatography mass spectrometry, gas chromatography, gas chromatography mass spectrometry, ICP mass spectrometry, atomic absorption, and related instrumentation plus components.
  • Services exposure is explicitly tracked: The company reports CrossLab services revenue (within the Agilent CrossLab Group), which indicates a recurring, services-led element alongside instrument sales.
  • Strong profitability metrics provided: For the period ending 2026-04-30, gross margin is 54.0% and operating margin is 21.7%.

Bear case

  • Segment mix concentration: Because a large portion of revenue is from the Life Science and Applied Markets Group (LSAG), changes in demand for instruments and components in life sciences and applied markets could pressure results.
  • Services performance can be sensitive: CrossLab includes services revenue, so weakness in customer lab activity, service utilization, or service demand could affect the company’s services growth.
  • Sales volatility tied to product cycles: The business sells complex analytical systems (for example, chromatography and mass spectrometry instruments), which can be exposed to timing of lab purchases and upgrades.
Valuation — source: SEC EDGAR (first-party)
Price$156.29
Market Cap$44.17B
P/E Ratio31.2
EV / EBITDA25.0
Price / Sales6.11
FCF Yield2.5%
DCF Value (model)$123.27
DCF Upside vs Price-21.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$6.95B
Net Margin18.8%
Revenue Growth (YoY)10.0%
EPS Growth (YoY)60.0%
FCF Growth (YoY)87.9%
Financial Health — source: SEC EDGAR
Altman Z-Score3.35 (safe)
Piotroski F-Score5/9 (moderate)
Valuation vs Sector & Industry
Stock P/E31.2
Sector P/E (Technology)33.9
Industry P/E (Measuring & Control Equipment)51.8
vs Sector-7.9%
vs Industry-39.7%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($4.64B)
Institutional Holders Tracked10
Congressional Trades (recent)10
Company
SectorTechnology
IndustryMeasuring & Control Equipment
CEOPadraig McDonnell
Employees17,900
CountryUS
IPO Date2001-01-17

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Waters Corporation (WAT)
  • Illumina, Inc. (ILMN)
  • Mettler-Toledo International Inc. (MTD)
  • Revvity, Inc. (RVTY)
  • Bio-Rad Laboratories, Inc. (BIO)
  • Avantor, Inc. (AVTR)
  • Bruker Corporation (BRKR)
  • 10x Genomics, Inc. (TXG)
A earnings history · A institutional & insider holders · A KPIs & operating metrics · A financials · A investor presentations & press releases · A SEC filings · A peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.